Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This is a prospective, interventional, single-arm, open-label, phase II study to evaluate the
safety and efficacy of niraparib monotherapy as neoadjuvant therapy in patients with advanced
ovarian cancer, primary peritoneal cancer, fallopian tube cancer ((FIGO stage III or IV), who
can not achieve R0 tumor reduction surgery after imaging evaluation or laparoscopic
evaluation or can not tolerate surgery.
Phase:
Phase 2
Details
Lead Sponsor:
Tongji Hospital
Collaborators:
Anhui Cancer Hospital Anhui Provincial Cancer Hospital First Affiliated Hospital of Suzhou Medical College Guangdong Provincial People's Hospital Hubei Cancer Hospital Hunan Cancer Hospital Jilin Provincial Tumor Hospital Obstetrics and Gynecology Hospital of Zhejiang University Qilu Hospital of Shandong University Renmin Hospital of Wuhan University Sun Yat-sen University The First Affiliated Hospital of Suzhou University